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Introduction
Hungry Bone Syndrome (HBS) may occur in patients who have 
undergone Parathyroidectomy for Primary Hyperparathyroidism 
(PHPT), and is characterised by prolonged severe hypocalcaemia. 
Patients who preoperatively showed a large parathyroid adenoma, high 
preoperative serum calcium, serum Parathyroid Hormone (PTH) and 
serum alkaline phosphatase levels, skeletal manifestations as osteitis 
fibrosa cystica, brown tumours and severe osteoporosis, and old age are 
exposed to the risk of developing HBS [1].
In hyperparathyroidism, hypercalcaemia is mainly due to increased 
bone turnover with enhanced osteoclastic bone activity and increased 
reabsorption of calcium in the renal tubules. After parathyroidectomy, 
the PTH stimulus is abruptly removed. The excessive osteoclastic activity 
shuts down, and is replaced by an avid osteoblastic activity, resulting in 
rapid and marked increase in bone calcium uptake, predisposing the 
patient to symptomatic hypocalcaemia [2].
Primary Hyperparathyroidism
The hormone secreted by the four parathyroid glands, parathyroid 
hormone, is a cornerstone of calcium metabolism. Parathyroid chief 
cells receptors are activated by low levels of serum ionised calcium and 
secrete PTH. It induces calcium bone osteoclasts-mediated resorption 
and renal tubular calcium reabsorption. Intestinal calcium absorption is 
enhanced as well throw PTH induced hydroxylation of 25-OHvitamin 
D3 to the activated form 1, 25-OH. By negative feed back, raised serum 
ionised calcium decreases PTH secretion to maintain adequate serum 
calcium levels [3].
Primary hyperparathyroidism (PHPT) is the commonest cause of 
hypercalcaemia, a condition that has become more frequently recorded 
because of popularization of routine screening tests that uncover PHPT 
well before symptoms appear [4].
Hypercalcaemia is defined as a raised serum total calcium level 
greater than 10.3 mg/dL (>2.58 mmol/L); severe hypercalcaemia, 
serum total calcium level greater than 14 mg/dL (>3.5 mmol/L), is 
associated with acute signs and symptoms. Mild hypercalcaemia is 
often asymptomatic.
Prevalence of PHPT in western countries is increasing as well [5] 
and ranges between 0.2% and 1%, with a gender imbalance between 
males and females of 1:3. Although it can occur at any age, this disease 
affects people of over 55 at a rate up to 2% [6-8].
Sporadic PHPT is the commonest form and accounts for more than 
85% of cases: it is supported by PT adenoma of the chief cells, affecting 
only one gland. PT hyperplasia accounts for less than 15% of cases and 
carcinoma is very rare (1% or less) [9].
PHPT may also be a part of some familial disorders, namely 
Multiple Endocrine Neoplasia (MEN) type 1 and type 2A, familial 
hyperparathyroidism-jaw tumour syndrome, neonatal severe 
hyperparathyroidism, and familial isolated hyperparathyroidism.
In MEN 1 (Wermer syndrome) PT hyperplasia is associated to 
endocrine pancreas tumours and pituitary tumours (3Ps: parathyroid, 
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Parathyroidectomy is the treatment of choice in patients with primary hyperparathyroidism (PHPT). This 
disease affects calcium metabolism at the level of bone tissue and renal tubules, resulting in hypercalcaemia, often 
asymptomatic, associated with hypophosphataemia and hypomagnesaemia.
Sudden suppression of parathyroid hormone (PTH), caused by successful parathyroidectomy, in patients with 
preoperative high levels of PTH and hypercalcaemia from enhanced bone turnover, may induce severe postoperative 
hypocalcaemia that may lead to symptoms of tetany. This relatively uncommon condition is known as “hungry bone 
syndrome” (HBS), because it is believed to be due mainly to enhanced bone formation.
Several risk factors have been advocated for HBS, and the syndrome is reported to be more likely to rise in 
subjects with severe preoperative bone disease. Other modifiable risk factors are preoperative vitamin D deficiency 
and high PTH and calcium levels.
Treatment of HBS is basically the administration of high amounts of calcium immediately after the onset of 
postoperative hypocalcaemia. Supplements of active metabolites of vitamin D, as well as magnesium in depleted 
subjects are complementary in supporting bone remineralization. Oral supplementation may be requested for months 
after parathyroidectomy.
Prevention is poorly documented, but it is reasonable to propose the correction of vitamin D deficit and the use of 
bisphosphonates aimed to lower PTH levels and bone resorption before parathyroidectomy.
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pancreas, pituitary). For the syndrome to be clinically manifest, the 
inherited germinal autosomal dominant mutation of the oncosuppressor 
gene MEN1, located on the chromosome 11, must be associated to 
somatic mutations. Other endocrine or cutaneous tumours may be 
present in up to 30% of the cases.
MEN 2 (Sipple syndrome) is characterized by medullary thyroid 
carcinoma and pheochromocytoma. The mutation of RET (REarranged 
during Transfection) proto-oncogene in the chromosome 10 is a 
genetic autosomal dominant disorder underlining this disease. PT 
hyperplasia or adenoma is involved in 10-20% and is the cause of 
hyperparathyroidism in MEN 2A. PT glands are not involved in MEN 
2B [10].
Another familial condition, inherited as an autosomal dominant 
disease, is familial hypocalciuric hypercalcaemia. It is characterized 
by an inactivating mutation in the calcium sensing receptors gene, 
generating increased levels of serum calcium and reduced sensitivity 
of the kidney to these increased levels, with resulting relative 
hypocalciuria. Unsuppressed or elevated serum PTH and typically 
normal renal function are seen as well, while hypercalcaemic symptoms 
are generally absent [11-14].
Parathyroidectomy
Parathyroidectomy is the only cure for PHPT in current practice. 
The purpose of surgical treatment in PHP is to remove enough 
abnormal parathyroid tissue to reduce the long-term destructive effects 
on bone and the negative effects of high serum calcium levels and keep 
the patient normocalcaemic.
The possibility that two or more PTs are responsible of 
hyperparathyroidism is a major problem of PT surgery, because a 
reliable preoperative diagnosis is not yet available. In fact, either 
echography and sestamibi scintigram often fail to show whether or not 
there is a single gland responsible for the serum PTH increase.
Since the advent of intraoperative PTH (IOPTH) dosage, the 
treatment of choice was bilateral cervical exploration to identify all 
the four PTs: removal of “enlarged” gland was then accomplished on 
the basis of surgeon’s judgement and reoperation for residual PHPT 
was frequent. Another risk of this extensive approach is postoperative 
permanent hypoparathyroidism secondary to excessive PT tissue 
removal [15]. Moreover, such an invasive approach increases the risk 
of injury to the laryngeal nerves. Intraoperative identification of the 
hyper-functioning PT gland(s) was performed then by radiolabeled 
sestamibi guided surgery: this technique is still particularly useful in 
redo operations. The background signal from other tissues and the 
rapid clearance of radiolabeled sestamibi prevented this method from 
gaining large acceptance in primary operations [16,17].
IOPTH monitoring is to date the most accurate way to be sure that 
the hyper-functioning PT has been effectively removed, and, along with 
improved preoperative imaging techniques, made minimally invasive 
parathyroidectomy (MIP) the favoured treatment. MIP has been shown 
as successful as bilateral cervical exploration, but safer, because the risk 
of injury to the recurrent laryngeal nerves is lower. Additionally, MIP 
is much more tolerated by the patients and showed to be cost effective 
[18-22].
A successful parathyroidectomy results in a sudden decrease of 
PTH (due to its short half-life) that is intraoperative monitored. PTH 
half-life is independent of renal function but is increased by body mass 
index.
PTH is rapidly metabolized (less than 4 minutes) in the kidney 
and liver by enzymatic rupture in two fragments [23] a biologically 
active N-terminal fraction and an inactive C-terminal fraction. Intact 
PTH assays are effective in measuring the kinetic of incretion of this 
hormone, because they measure either the hormone before degradation 
(1-84 aminoacids) and the N-terminal fragment (7-84 aminoacids), 
while they do not cross-react with the inactive C-terminal fragment.
Three IOPTH criteria are most commonly used currently: all refer 
to a basal sample, taken after induction of anaesthesia and intubation 
but before skin incision, versus a second sample taken 10 or 15 minutes 
after gland removal.
The first criterion is the serum PTH value decrease of more than 
50% from the highest pre-excision value (Miami criterion); drop of 
more than 50% from pre-incision IOPTH level at 10 minutes (Vienna 
criterion); decrease of more than 50% and into the normal laboratory 
range after 15 minutes of excision (Halle criterion) [24-27].
Hungry Bone Syndrome
Hungry bone syndrome is a complication of parathyroid excision 
surgery, occurring when the sudden decrease in serum PTH is 
associated to the enhanced calcium uptake by the demineralized 
bone. The PTH stimulus on renal tubular reabsorption of calcium falls 
abruptly too. The net effect of such calcium metabolism inversion is 
hypocalcaemia, that may typically cause symptoms of tetany.
Table 1 resumes the clinical presentation of hyper- and hypo- 
calcaemia.
Severe postparathyroidectomy hypocalcaemia has an estimated 
incidence of 12% (with an extremely wide range of 4 to 87%), and may 
be as much severe and prolonged as to be life threatening and require 
urgent intensive therapy.
It is noticeable that the most frequent presentation of symptoms 
of mild tetany occurs with serum calcium levels still in the range of 
normality. Prolonged hypercalcaemia secondary to PHPT may down 
regulate calcium receptors and a condition of relative hypocalcaemia 
may occur soon after PT excision, causing tingling and numbness of 
fingers or lips.
The predictive value of preoperative laboratory investigations 
(namely serum calcium, PTH, alkaline phosphatase, albumin, 
magnesium) is questioned, but observations seem to have the tendency 
to link higher probability of HBS to major alterations of these indicators.
HBS is currently considered actual till postoperative hypocalcaemia 
recovers after parathyroidectomy, and calcium supplementation can 
be safely interrupted. This occurs when bone turnover turns back to 
Symptoms of severe 
hypercalcaemia Symptoms of severe acute hypocalcaemia
Fatigue Syncope
Weakness Angina
Polydipsia Congestive heart failure (reversible)
Polyuria Perioral and/or finger tingling and numbness
Dehydration Carpopedal spasm, Chvostek sign, Trusseau sign
Nausea and/or vomiting Muscular cramps (back and lower limbs)
Abdominal pain Wheezing (from bronchospasm)
Constipation Dysphagia
Bone pain Voice changes (spasm of the larynx)
Mental status changes Irritability, mental status changes
Seizures and/or uncontrolled movements
Table 1: Symptoms of severe hypercalcaemia and severe acute hypocalcaemia.
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normal and the function of the residual non-pathologic glands regains 
normal PTH secretion levels [28]. 
Within 3-4 days of successful parathyroidectomy, serum calcium 
levels may drop to <2.1 mmol/L, but patients with HBS show a 
progression in decrease of calcaemia well beyond this term. The 
degree of serum calcium level fall is a function of preoperative PTH 
level and related bone turnover. Serum phosphate decreases as well for 
the duration of the syndrome, and alkaline phosphatase may remain 
elevated for months, because of its involvement in bone formation. A 
marker of bone formation, serum osteocalcin, has reported to maintain 
high levels up to one year after surgery, in some cases of severe 
preoperative osteoporosis [29]. 
Recovery of skeletal manifestations of PHPT is the consequence of 
the cure, and increase in bone mineral density has been documented to 
reach the remarkable percentages of 35-131% at one year [30]. 
Bone formation can be demonstrated both by conventional 
radiographies and bone scintigraphy. Recovery of sub-periosteal 
resorption can be showed at follow-up radiograms as well as 
remineralization of brown tumours. Pathological fractures heal more 
rapidly and osteolytic lesions tend to disappear [30-32]. 
A typical feature of calcium uptake in restoring bone is the 
“flare phenomenon” at skeletal scintigram: previously ignored or 
underestimated osteoclastic lesions show high calcium uptake activity 
after curative parathyroidectomy, a feature similar to that occurring 
in treated bone metastasis where bone resorption areas turn on bone 
formation ones. Since bone scintigraphy is not a routine issue in 
parathyroidectomy follow up, the incidence of this phenomenon is 
unknown, but in studied patients flare-up was observed after months 
of surgery [33-35]. 
How to Manage HBS
Serum calcium, phosphate and PTH have a circadian rhythm in 
healthy people: peak phosphate and nadir calcium levels are recorded 
at 3.00 a.m. On the contrary, nadir phosphate and peak calcium levels 
are recorded at 3.00 p.m. [36]. PTH rises and falls twice a day (late 
afternoon-early evening and late evening-early morning), reaching 
nadir at mid-morning. Gender differences exist in that premenopausal 
women show less rapid but longer overnight rise than men [37,38]. This 
rhythm is lost in PHPT and re-conquered after parathyroidectomy. 
Serum calcium and phosphate seem to be the most effective factors 
involved in the maintenance of this rhythm, but other endogenous 
factors have a role, growth hormone and prolactin appearing as the 
main actors [39]. 
After parathyroidectomy for PHPT, calcium levels decrease 
suddenly, and this phenomenon may be excessively amplified by 
magnification of bone formation.
The management of HBS must satisfy enhanced calcium request 
either in emergency and long-term settings.
Since hypocalcaemia occurs suddenly after surgery, it must be 
monitored in the first few hours of operation. Repeated blood samples 
are needed to assess the tendency to lowering serum calcium levels, and 
serum phosphate and magnesium must be monitored as well.
Not uncommonly, tetany symptoms can occur with normal serum 
calcium levels, an expression of relative hypocalcaemia.
Functional hypoparathyroidism may be enhanced by serum 
magnesium depletion (e.g. diabetes, diuretics, magnesium wasting renal 
disorders, alcoholism) or excess (diet magnesium supplementation in 
subjects with chronic renal diseases, laxatives, antiacids). Moreover, 
magnesium may suppress PTH release by activation of extracellular 
calcium-sensing receptors, a calcium-like effect [40]. 
High levels of serum phosphate are known to stimulate gene 
transcription and PTH secretion independently of calcium and/or 
calcitriol levels [36]. 
Depletion of vitamin D is often associated to PHPT, and restoration 
of normal levels of 25(OH) D is to be attained, given the importance of 
this vitamin for calcium metabolism.
Oral supplementation of large amounts of calcium (up to 12 grams 
per day) is required to treat HBS; intravenous calcium gluconate is 
administered in the acute presentation, until recovery from symptoms 
of tetany has been gained and oral administration can maintain 
adequate levels of serum calcium.
Electrocardiographic monitoring is advisable when intravenous 
administration of large amounts of calcium-containing solutions is 
required, to prevent the risk of dysrhythmias that may occur in case of 
too rapid correction of hypocalcaemia [41]. 
When administering calcium orally, the different content of calcium 
of current preparations has to be taken in account, because there is a 
wide variability in elemental calcium percentages: calcium carbonate 
has the most favourable rate (40%) followed by citrate (20%). Other 
preparations require a too large number of tablets to reach adequate 
serum calcium levels, and patient compliance to therapy results 
negatively affected [40]. 
The concomitant administration of vitamin D (as active forms) is 
mandatory, to support the needs of bone remineralization.
Restoration of normal levels of phosphate usually follows the 
normalization of serum calcium, and magnesium must be supplemented 
only in cases of hypomagnesaemia. Magnesium deficiency may require 
high replacement at high doses that can be administered intravenously 
as sulphate; when oral administration is sufficient, magnesium oxide 
may be employed successfully. Hypocalcaemia cannot be definitely 
resolved until normal levels of serum magnesium are obtained [42]. 
On a long term perspective, calcium and active vitamin D 
metabolites supplementation is guided by serum levels of calcium and 
25(OH) vitamin D. Markers of bone turnover are useful to determine 
the metabolic condition of the skeleton: its normalization is an indicator 
of stable resolution of HBS.
The conquest of normality in calcium metabolism and bone 
turnover may require several months and it is not uncommon for 
patients to need calcium and vitamin D supplementation for as long 
as one year.
Options to Prevent HBS
Since vitamin D depletion is detected in as much as 76% patients 
with PHPT [43], it has been considered a risk factor for developing 
postoperative hypocalcaemia and HBS [44,45]. 
Preoperative vitamin D supplementation in depleted patients 
resulted in decreased levels of PTH, better control of hypercalcaemia 
and bone turnover [46]. Although this practice seems to be justified 
and advisable, no randomized controlled study evaluated the impact 
of preoperative vitamin D restoring therapy on postoperative 
hypercalcaemia in PHPT.
Bone resorption is actually best managed with bisphosphonates. 
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These drugs are currently used in bone disorders associated with calcium 
mobilization for their osteoclastic inhibition and remineralization 
activity. The use of bisphosphonates to prevent HBS has been advocated, 
but their beneficial effects may only develop on a long-term basis and 
the normalization of alkaline phosphatase should be achieved before 
surgery is attempted.
Short-term bisphosphonate therapy, in fact, may reduce bone 
resorption, but decrease of bone formation needs a longer time to 
reduce calcium request: thus, hypocalcaemia may result severely 
enhanced after parathyroidectomy.
Although the theory is convincing, preoperative long-term 
administration of bisphosphonates to prevent HBS has no longer been 
tested in randomized controlled trials, and data from several limited 
series are conflicting [47-50]. 
Conclusion
In mild as well in severe PHPT parathyroidectomy allows to 
normalize either serum calcium and PTH. Bone resorption decreases 
and mineral density increases in patients successfully operated.
Minimally invasive parathyroidectomy is as effective as extended 
neck exploration for PT previously localized but largely safer in 
preserving laryngeal nerve function and integrity.
IOPTH monitoring is essential in the modern approach to 
parathyroidectomy.
HBS may occur as a complication of parathyroidectomy in patients 
whose PTH and serum calcium levels are very elevated preoperatively.
The incidence of HBS appears to decrease in time, possibly due to 
early diagnosis of hypercalcaemia and PHPT. Better management of 
bone resorption and appropriate preoperative treatment contributed to 
minimize the incidence of HBS.
Prevention of HBS with activated vitamin D in depleted subjects 
and bisphosphonates, in a long-term setting, is advisable, although 
evidence for the latter comes only from small uncontrolled series. 
Short-term bisphosphonates administration seems to be less useful 
and, in some instances, revealed to be a possible trigger to HBS.
Treatment of severe HBS after parathyroidectomy requires 
intravenous calcium administration under electrocardiographic 
monitoring, high dose activated vitamin D, intravenous magnesium 
sulphate or oral magnesium oxide in the case of deficiency.
Mild HBS may be managed with oral administration of large 
amounts of calcium, looking out for the mineral content of the 
preparation given.
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